Advocacy for Access to Nusinersen and Risdiplam
Advocacy for Access to Nusinersen and Risdiplam
Page last updated: 4th June 2026
14th May 2026: NICE recommends nusinersen and risdiplam for permanent NHS England funding
After 10 years of advocacy and campaigning, SMA UK is delighted to celebrate this hard-won milestones with the SMA Community, patient groups and clinicians.
The decision follows the National Institute for Health and Care Excellence’s extensive review of these two the treatments. The recommendations were finalised on 4th June 2026.
Read our Blog for more on this announcement >
What this means for children >
Biogen’s community statement >
What this means for the SMA Community
Approved treatments have traded the fear of decline for the power of stability. Daily life is no longer about regression, but the freedom to focus on living. It is a new era of certainty, where the focus is firmly on the path ahead.
